Incyte Corporation (INCY)

[surf1944]

7:42AM Incyte announced results from a Phase I/II study of Incyte's JAK inhibitor demonstrated marked and durable clinical benefits in patients with myelofibrosis (INCY) 14.03 : Co announced yesterday after the close that results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published in The New England Journal of Medicine. The Phase I/II study of 153 patients showed that 70% to 82% of myelofibrosis patients receiving oral INCB18424 twice daily experienced 25% or more reduction in palpable spleen size which was durable for more than one year of follow-up. More than half of subjects treated with an optimized dose regimen which began with 15 mg twice daily achieved at least a 50% reduction in palpable spleen size. Incyte retained rights for the development and potential commercialization of INCB18424 in the US and out-licensed the compound to Novartis for development and potential commercialization outside the US